{"id":"W2947072948","doi":"10.1200/jco.2019.37.15_suppl.4004","title":"Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Mallinckrodt; Clinical trial; Placebo; Phases of clinical research; Internal medicine; Surgery; Family medicine; Hepatocellular carcinoma; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003736006,0.001141277,0.00145391,0.0003895394,0.0004199352,0.00121425,0.0008760364,0.001321949,0.008320152],"category_scores_gemma":[0.001804366,0.0004753824,0.001708825,0.0003342703,0.0005058839,0.0009017732,0.0004056293,0.003230867,0.001507695],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001073042,"about_ca_system_score_gemma":0.001352752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000631678,"about_ca_topic_score_gemma":0.001517105,"domain_scores_codex":[0.9991461,0.0004518102,0.00005710721,0.0001233096,0.000106164,0.0001156225],"domain_scores_gemma":[0.9987065,0.0002861812,0.0002976276,0.0001096093,0.0001096494,0.0004904763],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8807041,0.02676816,0.003340468,0.001189916,0.003127645,0.0001379456,0.0001437096,0.001728531,0.01870193,0.0002648301,0.01016807,0.05372468],"study_design_scores_gemma":[0.7145987,0.2570197,0.01367562,0.0001009487,0.002417667,0.0002872777,0.00004401309,0.0008346974,0.003942897,0.0003369721,0.006697772,0.00004367454],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9613669,0.01042573,0.001262111,0.001574113,0.0004330779,0.005173223,0.01082107,0.0002745795,0.008669204],"genre_scores_gemma":[0.9752976,0.002929712,0.001606914,0.001648542,0.0002469611,0.00273267,0.01037515,0.00007559607,0.005086779],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008320152,"threshold_uncertainty_score":0.0278337,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1730982922476607,"score_gpt":0.4397241875760797,"score_spread":0.266625895328419,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}